Abiraterone
The metabolism of Metronidazole can be decreased when combined with Abiraterone.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Metronidazole.
Amiodarone
The metabolism of Metronidazole can be decreased when combined with Amiodarone.
Advertisement
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Metronidazole.
Anagrelide
Metronidazole may increase the QTc-prolonging activities of Anagrelide.
Apalutamide
The serum concentration of Metronidazole can be decreased when it is combined with Apalutamide.
Advertisement
Aprepitant
The serum concentration of Metronidazole can be increased when it is combined with Aprepitant.
Arsenic Trioxide
Metronidazole may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Metronidazole may increase the QTc-prolonging activities of Artemether.
Advertisement
Asenapine
Metronidazole may increase the QTc-prolonging activities of Asenapine.
Atazanavir
The metabolism of Metronidazole can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Metronidazole can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Metronidazole is combined with Atorvastatin.
Azithromycin
Metronidazole may increase the QTc-prolonging activities of Azithromycin.
Bedaquiline
Metronidazole may increase the QTc-prolonging activities of Bedaquiline.
Boceprevir
The metabolism of Metronidazole can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Metronidazole can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Metronidazole can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Metronidazole.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Metronidazole.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Metronidazole.
Busulfan
The serum concentration of Busulfan can be increased when it is combined with Metronidazole.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Metronidazole.
Capecitabine
The serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Metronidazole.
Carbamazepine
The metabolism of Metronidazole can be increased when combined with Carbamazepine.
Carbocysteine
The risk or severity of adverse effects can be increased when Metronidazole is combined with Carbocisteine.
Ceritinib
The serum concentration of Metronidazole can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Metronidazole.
Chloroquine
Metronidazole may increase the QTc-prolonging activities of Chloroquine.
Chlorpromazine
Metronidazole may increase the QTc-prolonging activities of Chlorpromazine.
Cholecalciferol
The metabolism of Metronidazole can be decreased when combined with Cholecalciferol.
Ciprofloxacin
Metronidazole may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Metronidazole may increase the QTc-prolonging activities of Cisapride.
Citalopram
Metronidazole may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
The metabolism of Metronidazole can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Metronidazole can be decreased when combined with Clemastine.
Clotrimazole
The metabolism of Metronidazole can be decreased when combined with Clotrimazole.
Clozapine
Metronidazole may increase the QTc-prolonging activities of Clozapine.
Cobicistat
The metabolism of Metronidazole can be decreased when combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Metronidazole.
Crisaborole
The metabolism of Metronidazole can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Metronidazole can be decreased when combined with Crizotinib.
Cyclosporine
The metabolism of Metronidazole can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Metronidazole can be decreased when it is combined with Dabrafenib.
Darunavir
The metabolism of Metronidazole can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Metronidazole can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Metronidazole can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Metronidazole can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Metronidazole can be decreased when combined with Delavirdine.
Dicumarol
The serum concentration of Dicoumarol can be increased when it is combined with Metronidazole.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metronidazole.
Diltiazem
The metabolism of Metronidazole can be decreased when combined with Diltiazem.
Disopyramide
Metronidazole may increase the QTc-prolonging activities of Disopyramide.
Disulfiram
The risk or severity of adverse effects can be increased when Disulfiram is combined with Metronidazole.
Dofetilide
Metronidazole may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Metronidazole may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Metronidazole may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The metabolism of Metronidazole can be decreased when combined with Dosulepin.
Doxycycline
The metabolism of Metronidazole can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Metronidazole can be decreased when combined with Doxycycline.
Dronedarone
Metronidazole may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Metronidazole may increase the QTc-prolonging activities of Droperidol.
Efavirenz
The metabolism of Metronidazole can be decreased when combined with Efavirenz.
Eliglustat
Metronidazole may increase the QTc-prolonging activities of Eliglustat.
Enzalutamide
The serum concentration of Metronidazole can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Metronidazole.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Metronidazole.
Erythromycin
The metabolism of Metronidazole can be decreased when combined with Erythromycin.
Escitalopram
Metronidazole may increase the QTc-prolonging activities of Escitalopram.
Ethanol
The risk or severity of adverse effects can be increased when Metronidazole is combined with Ethanol.
Etravirine
The metabolism of Metronidazole can be decreased when combined with Etravirine.
Flecainide
Metronidazole may increase the QTc-prolonging activities of Flecainide.
Floxuridine
The metabolism of Metronidazole can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Metronidazole can be decreased when combined with Fluconazole.
Fluindione
The serum concentration of Fluindione can be increased when it is combined with Metronidazole.
Fluorouracil
The serum concentration of Fluorouracil can be increased when it is combined with Metronidazole.
Fluoxetine
Metronidazole may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Metronidazole may increase the QTc-prolonging activities of Flupentixol.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Metronidazole.
Fluvoxamine
The metabolism of Metronidazole can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Metronidazole can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Metronidazole can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Metronidazole can be decreased when it is combined with Fosphenytoin.
Fusidate
The serum concentration of Metronidazole can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Metronidazole can be increased when it is combined with Fusidic Acid.
Gadobenate
Metronidazole may increase the QTc-prolonging activities of Gadobenic acid.
Gemfibrozil
The metabolism of Metronidazole can be decreased when combined with Gemfibrozil.
Gemifloxacin
Metronidazole may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Metronidazole may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Metronidazole may increase the QTc-prolonging activities of Goserelin.
Granisetron
Metronidazole may increase the QTc-prolonging activities of Granisetron.
Haloperidol
Metronidazole may increase the QTc-prolonging activities of Haloperidol.
Hypoxis hemerocallidea root extract
The serum concentration of Metronidazole can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Metronidazole.
Ibutilide
Metronidazole may increase the QTc-prolonging activities of Ibutilide.
Idelalisib
The metabolism of Metronidazole can be decreased when combined with Idelalisib.
Iloperidone
Metronidazole may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Metronidazole can be decreased when combined with Imatinib.
Indinavir
The metabolism of Metronidazole can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Metronidazole can be decreased when combined with Indinavir.
Irbesartan
The metabolism of Metronidazole can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Metronidazole can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Metronidazole can be decreased when combined with Isavuconazonium.
Isradipine
The metabolism of Metronidazole can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Metronidazole can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Metronidazole can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Metronidazole can be decreased when combined with Ketoconazole.
Leflunomide
The metabolism of Metronidazole can be decreased when combined with Leflunomide.
Lenvatinib
Metronidazole may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Metronidazole may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Metronidazole may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Metronidazole may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Metronidazole may increase the QTc-prolonging activities of Levofloxacin.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Metronidazole.
Lopinavir
The risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.
Losartan
The metabolism of Metronidazole can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Metronidazole.
Luliconazole
The serum concentration of Metronidazole can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Metronidazole can be decreased when it is combined with Lumacaftor.
Lumefantrine
Metronidazole may increase the QTc-prolonging activities of Lumefantrine.
Manidipine
The metabolism of Metronidazole can be decreased when combined with Manidipine.
Mebendazole
The risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Metronidazole.
Methadone
Metronidazole may increase the QTc-prolonging activities of Methadone.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Metronidazole.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Metronidazole.
Midostaurin
The metabolism of Metronidazole can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Metronidazole can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Metronidazole can be decreased when it is combined with Mitotane.
Moxifloxacin
Metronidazole may increase the QTc-prolonging activities of Moxifloxacin.
MYCOPHENOLATE
The serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.
Mycophenolic Acid
The serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.
Nefazodone
The metabolism of Metronidazole can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Metronidazole can be decreased when combined with Nelfinavir.
Netupitant
The serum concentration of Metronidazole can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Metronidazole can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Metronidazole can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Metronidazole.
Nilotinib
Metronidazole may increase the QTc-prolonging activities of Nilotinib.
Ofloxacin
Metronidazole may increase the QTc-prolonging activities of Ofloxacin.
Olaparib
The metabolism of Metronidazole can be decreased when combined with Olaparib.
Omeprazole
The metabolism of Metronidazole can be decreased when combined with Omeprazole.
Ondansetron
Metronidazole may increase the QTc-prolonging activities of Ondansetron.
Osimertinib
The serum concentration of Metronidazole can be increased when it is combined with Osimertinib.
Palbociclib
The serum concentration of Metronidazole can be increased when it is combined with Palbociclib.
Paliperidone
Metronidazole may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Metronidazole may increase the QTc-prolonging activities of Panobinostat.
Pazopanib
Metronidazole may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Metronidazole may increase the QTc-prolonging activities of Pentamidine.
Pentobarbital
The metabolism of Metronidazole can be increased when combined with Pentobarbital.
Perflutren
Metronidazole may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Metronidazole.
Phenindione
The serum concentration of Phenindione can be increased when it is combined with Metronidazole.
Phenobarbital
The serum concentration of Metronidazole can be decreased when it is combined with Phenobarbital.
Phenprocoumon
The serum concentration of Phenprocoumon can be increased when it is combined with Metronidazole.
Phenytoin
The serum concentration of Metronidazole can be decreased when it is combined with Phenytoin.
Picosulfuric Acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Metronidazole.
Pimozide
Metronidazole may increase the QTc-prolonging activities of Pimozide.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Metronidazole.
Posaconazole
The metabolism of Metronidazole can be decreased when combined with Posaconazole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Metronidazole.
Primaquine
Metronidazole may increase the QTc-prolonging activities of Primaquine.
Primidone
The serum concentration of Metronidazole can be decreased when it is combined with Primidone.
Procainamide
Metronidazole may increase the QTc-prolonging activities of Procainamide.
Promazine
Metronidazole may increase the QTc-prolonging activities of Promazine.
Propafenone
Metronidazole may increase the QTc-prolonging activities of Propafenone.
Pyrimethamine
The metabolism of Metronidazole can be decreased when combined with Pyrimethamine.
Quetiapine
Metronidazole may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Metronidazole may increase the QTc-prolonging activities of Quetiapine.
Quinidine
Metronidazole may increase the QTc-prolonging activities of Quinidine.
Quinine
Metronidazole may increase the QTc-prolonging activities of Quinine.
Ranolazine
The metabolism of Metronidazole can be decreased when combined with Ranolazine.
Rifabutin
The metabolism of Metronidazole can be increased when combined with Rifabutin.
Rifampin
The metabolism of Metronidazole can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Metronidazole can be increased when combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Metronidazole.
Ritonavir
The risk or severity of adverse effects can be increased when Ritonavir is combined with Metronidazole.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Metronidazole.
Rucaparib
The metabolism of Metronidazole can be decreased when combined with Rucaparib.
Saquinavir
The metabolism of Metronidazole can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Metronidazole can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Metronidazole can be decreased when used in combination with Sarilumab.
Secobarbital
The metabolism of Metronidazole can be increased when combined with Secobarbital.
Sildenafil
The metabolism of Metronidazole can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Metronidazole can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Metronidazole can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Metronidazole.
Sorafenib
The metabolism of Metronidazole can be decreased when combined with Sorafenib.
Sotalol
Metronidazole may increase the QTc-prolonging activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Metronidazole can be decreased when it is combined with St. John's Wort.
Sulfadiazine
The metabolism of Metronidazole can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Metronidazole can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Metronidazole can be decreased when combined with Sulfisoxazole.
Tegafur
The serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Metronidazole.
Telaprevir
The metabolism of Metronidazole can be decreased when combined with Telaprevir.
Telavancin
Metronidazole may increase the QTc-prolonging activities of Telavancin.
Telithromycin
The metabolism of Metronidazole can be decreased when combined with Telithromycin.
Tetrabenazine
Metronidazole may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Metronidazole may increase the QTc-prolonging activities of Thioridazine.
Ticagrelor
The metabolism of Metronidazole can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Metronidazole can be decreased when combined with Ticlopidine.
Tipranavir
The risk or severity of adverse effects can be increased when Metronidazole is combined with Tipranavir.
Tocilizumab
The serum concentration of Metronidazole can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Metronidazole can be decreased when combined with Tolbutamide.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Metronidazole.
Toremifene
Metronidazole may increase the QTc-prolonging activities of Toremifene.
Trimethoprim
The metabolism of Metronidazole can be decreased when combined with Trimethoprim.
Valproate
The metabolism of Metronidazole can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Metronidazole can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Metronidazole can be decreased when combined with Valsartan.
Vandetanib
Metronidazole may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
The serum concentration of Metronidazole can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Metronidazole can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Metronidazole can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Metronidazole can be decreased when combined with Voriconazole.
Warfarin
The serum concentration of Warfarin can be increased when it is combined with Metronidazole.
Zafirlukast
The metabolism of Metronidazole can be decreased when combined with Zafirlukast.
Ziprasidone
Metronidazole may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Metronidazole may increase the QTc-prolonging activities of Zuclopenthixol.